VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis

American Journal of Pathology

Volumn 176, Issue 5, 2010, Pages 2269-2282

  Seagroves, Tiffany N ^a   Peacock, Danielle L ^a,b   Liao, Debbie ^c,d,f   Schwab, Luciana P ^a   Krueger, Robin ^b   Handorf, Charles R ^a   Haase, Volker H ^e   Johnson, Randall S ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROLACTIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LACTATION; LUNG ALVEOLUS EPITHELIUM; MAMMARY GLAND; MICROVASCULATURE; MOUSE; NONHUMAN; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; WESTERN BLOTTING;

EID: 77952080173     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090310     Document Type: Article

References (75)

1. Ohh M: Ubiquitin pathway in VHL cancer syndrome. Neoplasia 2006, 8:623-629
2. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO: Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3:e47
3. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL: Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 2003, 63:6130-6134
4. Vengellur A, Woods BG, Ryan HE, Johnson RS, LaPres JJ: Gene expression profiling of the hypoxia signaling pathway in hypoxia-inducible factor 1alpha null mouse embryonic fibroblasts. Gene Expr 2003, 11:181-197 (Pubitemid 37516650)
5. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH: von Hippel-Lindau disease. Lancet 2003, 361:2059-2067
6. Sano T, Horiguchi H: Von Hippel-Lindau disease. Microsc Res Tech 2003, 60:159-164
7. Corless CL, Kibel AS, Iliopoulos O, Kaelin WG, Jr.: Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 1997, 28:459-464
8. Lantzsch T, Hefler L, Koebl H, Lampe D: Expression of the von Hippel-Lindau gene protein in breast cancer tissue. Gynecol Oncol 2002, 84:186-187 (Pubitemid 34056491)
9. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B, Linehan WM: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85-90
10. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, Lerman MI, Yao M: Frequent somatic mutations and loss of heterozygosity of the von Hippel- Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994, 54:2852-2855
11. Dannenberg H, De Krijger RR, van der Harst E, Abbou M, Y IJ, Komminoth P, Dinjens WN: Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. Int J Cancer 2003, 105:190-195 (Pubitemid 36505320)
12. Miyakis S, Sourvinos G, Liloglou TL, Stathopoulos GP, Field JK, Spandidos DA: The Von Hippel-Lindau (VHL) tumor-suppressor gene is not mutated in sporadic human colon adenocarcinomas. Int J Cancer 2000, 88:503-505
13. Sourvinos G, Miyakis S, Liloglou TL, Field JK, Spandidos DA: Von Hippel-Lindau tumour suppressor gene is not involved in sporadic human breast cancer. Tumour Biol 2001, 22:131-136 (Pubitemid 32245408)
14. Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG: The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells. Int J Mol Med 2007, 20:605-611
15. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835
16. Bos R, Zhong H, Hanrahan CF, Mommers E, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1a during breast carcinogenesis. J Natl Cancer Instit 2001, 93:309-314 (Pubitemid 32219818)
17. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97:1573-1581 (Pubitemid 36297788)
18. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, Charpin C: Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005, 116:734-739 (Pubitemid 41099705)
19. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB: Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006, 12:4562-4568
20. Seagroves TN, Hadsell D, McManaman J, Palmer C, Liao D, McNulty W, Welm B, Wagner KU, Neville M, Johnson RS: HIF1alpha is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland. Development 2003, 130:1713-1724 (Pubitemid 36527529)
21. Liao D, Corle C, Seagroves TN, Johnson RS: Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007, 67:563-572 (Pubitemid 46192193)
22. Tang N, Mack F, Haase VH, Simon MC, Johnson RS: pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol 2006, 26:2519-2530
23. Gnarra JR, Ward JM, Porter FD, Wagner JR, Devor DE, Grinberg A, Emmert-Buck MR, Westphal H, Klausner RD, Linehan WM: Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 1997, 94:9102-9107 (Pubitemid 27357789)
24. Pfander D, Kobayashi T, Knight MC, Zelzer E, Chan DA, Olsen BR, Giaccia AJ, Johnson RS, Haase VH, Schipani E: Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development. Development 2004, 131:2497-2508 (Pubitemid 38877655)
25. Rankin EB, Tomaszewski JE, Haase VH: Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 2006, 66:2576-2583
26. Haase VH: The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Semin Cell Dev Biol 2005, 16:564-574
27. Doedens A, Johnson RS: Transgenic models to understand hypoxia-inducible factor function. Methods Enzymol 2007, 435:87-105
28. Boutin AT, Weidemann A, Fu Z, Mesropian L, Gradin K, Jamora C, Wiesener M, Eckardt KU, Koch CJ, Ellies LG, Haddad G, Haase VH, Simon MC, Poellinger L, Powell FL, Johnson RS: Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell 2008, 133:223-234
29. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R, Hennighausen L: Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 2001, 10:545-553 (Pubitemid 34043179)
30. Boulanger CA, Wagner KU, Smith GH: Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression. Oncogene 2005, 24:552-560
31. Haase VH, Glickman JN, Socolovsky M, Jaenisch R: Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A 2001, V98:1583-1588 (Pubitemid 32165542)
32. Ryan H, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit J, Jonhson R: Hypoxia-inducible factor-1alpha is a positive regulator in solid tumor growth. Cancer Res 2000, 60:4010-4015 (Pubitemid 30636574)
33. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, Furth PA, Hennighausen L: Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 1997, 25:4323-4330 (Pubitemid 27485212)
34. Seagroves TN, Krnacik S, Raught B, Gay J, Burgess-Beusse B, Darlington GJ, Rosen JM: C/EBPbeta, but not C/EBPalpha, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. Genes Dev 1998, 12:1917-1928 (Pubitemid 28304343)
35. Seagroves TN, Lydon JP, Hovey RC, Vonderhaar BK, Rosen JM: C/EBPbeta (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development. Mol Endocrinol 2000, 14:359-368
36. McManaman JL, Neville MC: Mammary physiology and milk secretion. Adv Drug Deliv Rev 2003, 55:629-641
37. Anderson SM, Rudolph MC, McManaman JL, Neville MC: Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis! Breast Cancer Res 2007, 9:204
38. Rosen JM, Wyszomierski SL, Hadsell D: Regulation of milk protein gene expression. Annu Rev Nutr 1999, 19:407-436 (Pubitemid 29380611)
39. Arias-Stella J: The Arias-Stella reaction: facts and fancies four decades after. Adv Anat Pathol 2002, 9:12-23
40. Henry MD, Triplett AA, Oh KB, Smith GH, Wagner KU: Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice. Oncogene 2004, 23:6980-6985
41. Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA: Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Oncogene 2006, 25:3325-3334
42. Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA: Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 2009, 4:e7669
43. Wagner KU, Boulanger CA, Henry MD, Sgagias M, Hennighausen L, Smith GH: An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development 2002, 129:1377-1386 (Pubitemid 34874159)
44. Keith B, Simon MC: Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129:465-472 (Pubitemid 46660978)
45. Hu CJ, Iyer S, Sataur A, Covello KL, Chodosh LA, Simon MC: Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol 2006, 26:3514-3526
46. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, Bondesson M: Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005, 9:617-628 (Pubitemid 41555144)
47. Kaidi A, Williams AC, Paraskeva C: Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007, 9:210-217 (Pubitemid 46420864)
48. Brown JM, Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998, 58:1408-1416
49. Zhang M, Rosen JM: Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev 2006, 16:60-64 (Pubitemid 43089613)
50. Rich JN: Cancer stem cells in radiation resistance. Cancer Res 2007, 67:8980-8984 (Pubitemid 47535877)
51. Rich JN, Bao S: Chemotherapy and cancer stem cells. Cell Stem Cell 2007, 1:353-355
52. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS: Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004, 6:R605-R615
53. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z: GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008, 13:141-152 (Pubitemid 351163164)
54. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE: Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88 (Pubitemid 43053633)
55. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ: Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997 (Pubitemid 43292419)
56. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM: Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008, 68:4674-4682
57. Matulka LA, Triplett AA, Wagner KU: Parity-induced mammary epithelial cells are multipotent and express cell surface markers associated with stem cells. Dev Biol 2007, 303:29-44
58. Creamer BA, Triplett AA, Wagner KU: Longitudinal analysis of mammogenesis using a novel tetracycline-inducible mouse model and in vivo imaging. Genesis 2009, 47:234-245
59. Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M, Santini D, Ceccarelli C, Chieco P, Bonafe M: p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 2007, 25:807-815 (Pubitemid 46354241)
60. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN: Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513
61. Hovey RC, Goldhar AS, Baffi J, Vonderhaar BK: Transcriptional regulation of vascular endothelial growth factor expression in epithelial and stromal cells during mouse mammary gland development. Mol Endocrinol 2001, 15:819-831 (Pubitemid 32411319)
62. Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K: Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol 1998, 177:439-452
63. Rossiter H, Barresi C, Ghannadan M, Gruber F, Mildner M, Fodinger D, Tschachler E: Inactivation of VEGF in mammary gland epithelium severely compromises mammary gland development and function. FASEB J 2007, 21:3994-4004
64. Maynard MA, Ohh M: Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 2004, 24:1-13
65. Aprelikova O, Wood M, Tackett S, Chandramouli GV, Barrett JC: Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res 2006, 66:5641-5647
66. Blancher C, Moore JW, Talks KL, Houlbrook S, Harris AL: Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 2000, 60:7106-7113
67. Czyzyk-Krzeska MF, Meller J: von Hippel-Lindau tumor suppressor: not only HIF's executioner. Trends Mol Med 2004, 10:146-149
68. Frew IJ, Krek W: Multitasking by pVHL in tumour suppression. Curr Opin Cell Biol 2007, 19:685-690
69. Lolkema MP, Mans DA, Snijckers CM, van Noort M, van Beest M, Voest EE, Giles RH: The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2. FEBS Lett 2007, 581:4571-4576
70. Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG, Jr., Ohh M: pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol 2004, 24:3251-3261
71. Chitalia VC, Foy RL, Bachschmid MM, Zeng L, Panchenko MV, Zhou MI, Bharti A, Seldin DC, Lecker SH, Dominguez I, Cohen HT: Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol 2008, 10:1208-1216
72. Young AP, Schlisio S, Minamishima YA, Zhang Q, Li L, Grisanzio C, Signoretti S, Kaelin WG, Jr.: VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol 2008, 10:361-369
73. Wagner KU, Krempler A, Triplett AA, Qi Y, George NM, Zhu J, Rui H: Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol 2004, 24:5510-5520
74. Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX, Robinson GW, Hennighausen L: Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 2004, 24:8037-8047
75. Joung YH, Lim EJ, Lee MY, Park JH, Ye SK, Park EU, Kim SY, Zhang Z, Lee KJ, Park DK, Park T, Moon WK, Yang YM: Hypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells. Exp Mol Med 2005, 37:353-364